AI summary
90% confidenceMEC research focusing on bioelectrochemical. Ticagrelor is a directly acting cyclopentyltriazolo-pyrimidine which does not require conversion into an active metabolite. It inhibits the P2Y12 receptors on platelets reversibly. Unlike clop...
Generated by MESSAI extraction pipeline · review against source PDF
Reported parameters
No values extracted from this paper yet.
No 3D model is mapped to this paper yet. Parameter ranges above still place reported values on the literature distribution.
Abstract
Ticagrelor is a directly acting cyclopentyltriazolo-pyrimidine which does not require conversion into an active metabolite. It inhibits the P2Y12 receptors on platelets reversibly. Unlike clopidogrel and prasugrel, resistance to ticagrelor is rarely reported. Various mechanisms have been proposed for this resistance. The case of a 62-year-old man with diabetes who had undergone index percutaneous coronary intervention (PCI) 22 days previously is described. The patient presented to us with stent thrombosis. His primary PCI was successfully carried out with a drug-eluting stent. He showed resistance to ticagrelor on thromboelastography platelet mapping. He responded well to prasugrel (another P2Y12 inhibitor) in combination with aspirin.
Keywords
Identifiers
- Journal
- European Journal of Case Reports in Internal Medicine
- Year
- 2021